Oral administration of cholera toxin B subunit conjugated to myelin basic protein protects against experimental autoimmune encephalomyelitis by inducing transforming growth factor-β-secreting cells and suppressing chemokine expression

International Immunology

Volumn 12, Issue 10, 2000, Pages 1449-1457

  Sun, Jia Bin ^a   Xiao, Bao Guo ^b   Lindblad, Marianne ^a   Li, Bin Ling ^a   Link, Hans ^b   Czerkinsky, Cecil ^a,c   Holmgren, Jan ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c INSERM   (France)

Author keywords

Cholera toxin B subunit; Experimental autoimmune encephalomyelitis; Myelin basic protein; Transforming growth factor

Indexed keywords

ANTIINFLAMMATORY AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CHOLERA TOXIN; CHOLERA TOXIN B SUBUNIT; FREUND ADJUVANT; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELIN BASIC PROTEIN; RANTES; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL SECRETION; CONTROLLED STUDY; DOWN REGULATION; DRUG CONJUGATION; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LEUKOCYTE COUNT; LYMPH NODE; LYMPHATIC DRAINAGE; MESENTERY LYMPH NODE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN; SPINAL CORD; T LYMPHOCYTE; TH1 CELL;

EID: 0033815173     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/12.10.1449     Document Type: Article

References (36)

1. T cell requirement for experimental allergic encephalomyelitis induction in the rat
2. Adoptive transfer of experimental allergic encephalomyelitis with activated spleen cells: Comparison on in vivo activation of concanvalin A
3. The rapid isolation of clonal antigen specific lines capable of mediating autoimmune encephalomyelitis
4. Spontaneous remission and acquired resistance to autoimmune encephalomyelitis (EAE) are associated with suppression of T cell reactivity: Suppressed EAE effector T cells recovered as T cell lines
5. Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein
6. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments
7. Oral tolerance with copolymer 1 for the treatment of multiple sclerosis
8. Cholera toxin B subunit: An effective transmucosal carrier-delivery system for induction of peripheral immunological tolerance
9. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit USA
10. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes
11. Treatment of experimental autoimmune arthritis by nasal administration of a type II collagen-cholera toxoid conjugate vaccine
12. Oral vaccination, mucosal immunity and oral tolerance with special reference to cholera toxin
13. Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development
14. Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody response in salivary glands and extramucosal tissues
15. 1-ELISA) procedure
16. Intranasal administration of a Schistosoma mansoni glutathione S-transferase-cholera toxoid conjugate vaccine evokes anti-parasitic and anti-pathological immunity in mice
17. Adoptive transfer of experimental allergic encephalomyelitis: Incubation of rat spleen cells with specific antigen
18. Organ-specific autoantigens induce transforming growth factor-β mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis
19. Sensitive mRNA detection using unfixed tissue: Combined radioactive and non-radioactive in situ hybridization histochemistry
20. Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy
21. Oral tolerance immune mechanisms and treatment of autoimmune diseases
22. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with down-regulation of inflammatory cytokines and differential up-regulation factor beta, interleukin 4, and prostaglandin E expression in the brain
23. Induction of anergy and/or active suppression in oral tolerance is determined by frequency of feeding and antigen dosage
24. Oral tolerance: Immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens
25. IL-4 is a differentiation factor for transforming growth factor-beta secreting T(h)3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis
26. Mice with a disrupted IFN-γ gene are susceptible to induction of experimental autoimmune encephalomyelitis (EAE)
27. Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system
28. Interferon-gamma-induced oligodendrocyte cell death: Implications for the pathogenesis of multiple sclerosis
29. Chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice: Enhancement by monoclonal antibodies against interferon-γ
30. Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-γ
31. Specific T-cell tolerance may reflect selective activation of lymphokine synthesis
32. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen
33. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems
34. Actions of cholera toxin and the prevention and treatment of cholera
35. Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1alpha and monocyte chemotactic protein-1
36. Identification of cell types producing RANTES, MIP-1 alpha and MIP-1 beta in rat experimental autoimmune encephalomyelitis by in situ hybridization